In-hospital and Readmission Outcomes With Percutaneous Balloon Mitral Valvuloplasty.
Curr Probl Cardiol
; 47(12): 101367, 2022 Dec.
Article
em En
| MEDLINE
| ID: mdl-36007617
ABSTRACT
Percutaneous balloon mitral valvuloplasty (PBMV) is primarily performed for rheumatic mitral stenosis (MS). Therefore, limited data exist on PBMV in countries with a low incidence of rheumatic disease. Using the Nationwide Readmission Database, we examined trends in in-hospital mortality and 30-day readmission among patients who received PBMV for rheumatic and non-rheumatic MS. We also examined the change in 90-day hospitalization rate before vs after PBMV. Between 2016 and 2019, there were 1109 hospitalizations in which patients received PBMV for rheumatic (n = 955, 86.1%) vs non-rheumatic MS (nâ¯=â¯154, 13.9%). The all-cause in-hospital mortality for rheumatic and non-rheumatic MS did not change over time (0.9%â¯ââ¯2.0%, Pâ¯=â¯0.94, and 5.9%â¯ââ¯9.5%, Pâ¯=â¯0.09 respectively). Similarly, the 30-day readmission for patients with rheumatic and non-rheumatic MS did not change over time (12.4%â¯ââ¯9.9%, Pâ¯=â¯0.26, and 4.4%â¯ââ¯10.5%, Pâ¯=â¯0.30, respectively). The 90-day all-cause hospitalization rate remained the same before vs after PBMV for rheumatic and non-rheumatic MS (25.5%â¯ââ¯21.8%; Pâ¯=â¯0.14, and 24.0%â¯ââ¯33.7%; Pâ¯=â¯0.19, respectively). Although no statistically significant change was noted over time for trends in in-hospital mortality, 30-day readmission, or even in the change in 90-day all-cause hospitalizations before and after PBMV for both types of MS, among those with non-rheumatic MS, there was a signal of an increase in the in-hospital mortality, and 30-day readmission, even more, there was 29% relative increase in 90-day hospitalizations after PBMV. Future studies are needed to examine the role of PBMV in patients with non-rheumatic MS.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Cardiopatia Reumática
/
Valvuloplastia com Balão
/
Estenose da Valva Mitral
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article